Exciting news at TBDreamDB! The Database is currently undergoing complete redesign and data evaluation. The database will be converted to a fully searchable relational Database with a new look front end website as well
We hope to have the beta design up and running towards the end of 2011 early 2012. Any feedback would be great, simply contact us at the curator email below.
Also please keep sending in any errors you find in the dataset. The data is being evaluated and corrected as it is being inserted into the new database format. -Your Emails are much appreciated!
(April 12 2010)
We have now released an updated version of the database encompassing all the novel mutations and frequency distribution data retreieved from papers published up to December 2009.
In this update we also provide links to TBDB and TubercuList for information about the individual genes. Finally, we also provide links to PubMed for the published papers from which the data have been retrieved.
(June 23 2009)
We have updated the rpoB pages to fix the bugs with displaying the High Confidence Mutations. Since we have received a lot of comments about the codon position numbering system of rpoB we have also decided to show the E.coli positions instead of the M.tuberculosis H37Rv positions. As before, you can find both E.coli and M.tuberculosis in the downloadable files below!
Inclusion criteria for new mutations
We will include novel mutations found in clinical isolates of TB if they must fulfill the following criteria:
- They are from published studies of clinical M.tuberculosis isolates.
- They occur in isolates that have been characterized by phenotypic drug sensitivity testing.
- Mutations are identified by specification of the gene, nucleotide position and the nucleotide and/or amino acid change.
Inclusion criteria for new frequency data
For studies to be included in the database describing the frequency of common mutations associated with drug resistance in M. tuberculosis, they must fulfill the following criteria:
- They must be studies of clinical M. tuberculosis isolates.
- They must have large sample sizes. Cut-offs for sample sizes for ETH, SM, FLQ and PZA have been determined empirically depending on the ten largest studies published so far.
- Isoniazid: a minimum of 100 resistant isolates.
- Rifampicin: a minimum of 100 resistant isolates.
- Ethambutol: a minimum of 50 resistant isolates.
- Streptomycin: a minimum of 36 resistant isolates.
- Fluoroquinolones: a minimum of 35 resistant isolates.
- Pyrazinamide: a minimum of 33 resistant isolates.
- They must report on phenotypic drug sensitivity testing for all isolates.
- They must use validated methods to identify drug resistance mutations.
- They must identify the nucleotide position and the nucleotide change.
- They must specify the number of resistant and sensitive isolates carrying a specific mutation.